Gluconeogenesis

Gluconeogenesis (literally "new glucose formation") is the anabolic eleven-step metabolic pathway that synthesizes D-glucose from non-carbohydrate three- and four-carbon precursors—principally lactate, pyruvate, glycerol, propionate, and glucogenic amino acids. In mammals, several tissues depend almost entirely on glucose as their primary metabolic fuel: the human brain and central nervous system alone consume approximately 120 g of glucose per day (out of ~160 g total daily bodily utilization), while erythrocytes, the renal medulla, the cornea, and anaerobically contracting skeletal muscle lack mitochondria or oxidative capacity and rely on glycolysis. Because total hepatic and muscle glycogen reserves store only ~180–200 g of mobilizable glucose—sufficient for 12 to 24 hours of fasting—gluconeogenesis is indispensable for maintaining euglycemia (4.0–5.5 mM blood glucose) during overnight fasting, prolonged starvation, and prolonged exercise.

In vertebrates, gluconeogenesis occurs predominantly in the parenchymal hepatocytes of the liver (~85–90% of physiological output) and the proximal convoluted tubule cells of the renal cortex (~10–15% under normal fasting, rising to ~40% during chronic starvation or metabolic acidosis), with minor activity in intestinal enterocytes. While seven of the ten enzymatic reactions of glycolysis are near-equilibrium reversible reactions (Δ*G* ≈ 0 kJ/mol) shared directly by both pathways, three glycolytic steps are strongly exergonic and thermodynamically irreversible in vivo. Gluconeogenesis circumvents these three energetic barriers using four specialized bypass enzymes partitioned across the mitochondrial matrix, cytosol, and endoplasmic reticulum lumen.

The carbon skeleton for gluconeogenesis enters the pathway at pyruvate, oxaloacetate, or dihydroxyacetone phosphate (DHAP) via four principal metabolic inputs:

1. Lactate (The Cori Cycle): Erythrocytes and exercising type II skeletal muscle fibers convert glucose into L-lactate via lactic acid fermentation and release it into the bloodstream. Hepatocytes take up circulating lactate and oxidize it back to pyruvate in the cytosol via lactate dehydrogenase (LDH), generating cytosolic NADH directly required for the glyceraldehyde-3-phosphate dehydrogenase step.
2. Glucogenic Amino Acids (The Glucose–Alanine Cycle): During fasting or proteolysis, peripheral muscle transaminates pyruvate with glutamate to produce L-alanine, which travels to the liver and is deaminated back to pyruvate by alanine aminotransferase (ALT). In total, 18 of the 20 standard proteinogenic amino acids (all except strictly ketogenic leucine and lysine) are glucogenic, entering as pyruvate or as citric acid cycle intermediates (α-ketoglutarate, succinyl-CoA, fumarate, or oxaloacetate) that are oxidized to oxaloacetate.
3. Glycerol: Hydrolysis of adipose triacylglycerols by hormone-sensitive lipase releases three fatty acids and one molecule of glycerol. The liver takes up glycerol and phosphorylates it via glycerol kinase (using ATP) to sn-glycerol-3-phosphate, which glycerol-3-phosphate dehydrogenase oxidizes into the triose phosphate intermediate DHAP.
4. Propionate (Propionyl-CoA): Oxidation of odd-chain fatty acids and branched-chain amino acids (valine, isoleucine)—as well as microbial fermentation of cellulose in ruminants—yields propionyl-CoA, which is carboxylated and rearranged (via biotin- and vitamin B₁₂-dependent enzymes) into succinyl-CoA.

In glycolysis, three kinase/phosphotransferase steps exhibit large negative cellular free energy changes (Δ*G* ≪ 0) and cannot run in reverse under physiological metabolite concentrations. Gluconeogenesis bypasses them through dedicated hydrolytic or carboxylation–decarboxylation reactions:

First Bypass: Pyruvate to Phosphoenolpyruvate (PC and PEPCK)

Because the direct phosphorylation of pyruvate to phosphoenolpyruvate (PEP) is endergonic by Δ*G*°' = +31.4 kJ/mol, cells couple two nucleoside triphosphate cleavages via a carboxylation–decarboxylation sequence:

1. Pyruvate Carboxylase (PC): Cytosolic pyruvate is imported into the mitochondrial matrix via the mitochondrial pyruvate carrier. There, homotetrameric pyruvate carboxylase—containing a covalently tethered biotin prosthetic group on a conserved lysine residue (biocytin)—uses ATP to carboxylate biotin with bicarbonate (HCO₃⁻), then transfers the activated carboxyl group to pyruvate to form four-carbon oxaloacetate (OAA). PC is obligately activated allosterically by acetyl-CoA: only when mitochondrial acetyl-CoA accumulates (signaling either abundant fatty acid β-oxidation or TCA cycle saturation) is pyruvate directed into OAA.
2. Malate Shuttle and PEP Carboxykinase (PEPCK): Because the inner mitochondrial membrane lacks an oxaloacetate transporter, when pyruvate or alanine is the precursor, mitochondrial malate dehydrogenase reduces OAA to L-malate (consuming mitochondrial NADH), which exits to the cytosol via the malate–α-ketoglutarate carrier and is re-oxidized to OAA + cytosolic NADH (supplying the reducing equivalents needed later in the pathway). When lactate is the precursor (which already generated cytosolic NADH via LDH), mitochondrial OAA is converted directly to PEP inside the matrix by the mitochondrial isozyme PEPCK-M or exported as aspartate. In either compartment, phosphoenolpyruvate carboxykinase (PEPCK) uses GTP to phosphorylate and simultaneously decarboxylate OAA into PEP + GDP + CO₂. The loss of the transient CO₂ group (originally added by PC) provides the thermodynamic driving force for generating the high-energy enol-phosphate bond of PEP (Δ*G*°' = +0.8 kJ/mol).

Second and Third Bypasses: FBPase-1 and Glucose-6-Phosphatase

Once PEP is synthesized in the cytosol, the reversible glycolytic enzymes enolase, phosphoglycerate mutase, phosphoglycerate kinase (consuming 1 ATP per triose), glyceraldehyde-3-phosphate dehydrogenase (consuming 1 NADH per triose), triose phosphate isomerase, and aldolase condense two triose phosphates into fructose-1,6-bisphosphate (F-1,6-BP).

• Second Bypass (FBPase-1): The rate-limiting commitment step of gluconeogenesis is the exergonic hydrolysis of the C1 phosphate ester of F-1,6-BP by cytosolic fructose-1,6-bisphosphatase-1 (FBPase-1): F-1,6-BP + H₂O → Fructose-6-phosphate (F6P) + P_i (Δ*G*°' = −16.3 kJ/mol). Phosphoglucose isomerase then isomerizes F6P to glucose-6-phosphate (G6P).
• Third Bypass (G6Pase): In the final step, G6P is transported by the T1 translocase across the membrane of the smooth endoplasmic reticulum (ER), where the integral membrane enzyme glucose-6-phosphatase hydrolyzes G6P into free D-glucose and inorganic phosphate (P_i) inside the ER lumen (Δ*G*°' = −13.8 kJ/mol). Free glucose and P_i return to the cytosol via T2/T3 transporters, and glucose exits the hepatocyte into systemic circulation through bidirectional GLUT2 transporters. Skeletal muscle and brain tissue lack glucose-6-phosphatase, ensuring that their G6P remains trapped intracellularly for local energy utilization.

Overall Energetic Cost vs. Glycolysis

Whereas converting one molecule of glucose to two molecules of pyruvate via glycolysis yields a net gain of 2 ATP and 2 NADH, synthesizing one molecule of glucose from two molecules of pyruvate via gluconeogenesis requires six high-energy nucleoside triphosphate bonds (4 ATP and 2 GTP) plus two molecules of NADH:

2 Pyruvate + 4 ATP + 2 GTP + 2 NADH + 2 H⁺ + 6 H₂O → D-Glucose + 4 ADP + 2 GDP + 6 P_i + 2 NAD⁺

Because of this 4-ATP net difference per cycle, simultaneous uninhibited operation of glycolysis and gluconeogenesis would constitute a wasteful futile (substrate) cycle hydrolyzing 4 NTPs to heat.

Allosteric and Hormonal Regulation by Fructose-2,6-Bisphosphate

To prevent futile cycling, glycolysis and gluconeogenesis are reciprocally regulated at the PFK-1 / FBPase-1 substrate node by cellular energy charge and endocrine hormones:

• Adenylate Energy Charge: High intracellular AMP and ADP (signaling ATP depletion) allosterically activate glycolytic PFK-1 while inhibiting gluconeogenic FBPase-1; conversely, high ATP and citrate inhibit PFK-1 and activate FBPase-1.
• Fructose-2,6-Bisphosphate (F-2,6-BP) Switch: Synthesized and degraded by the bifunctional enzyme PFK-2/FBPase-2, F-2,6-BP is a potent allosteric activator of PFK-1 and competitive/allosteric inhibitor of FBPase-1. During fasting, pancreatic α-cells secrete glucagon, elevating hepatic cAMP and activating protein kinase A (PKA). PKA phosphorylates Ser32 on PFK-2/FBPase-2, inactivating its kinase domain and activating its phosphatase domain, which destroys F-2,6-BP, relieves inhibition of FBPase-1, and stimulates gluconeogenesis. In the fed state, insulin activates protein phosphatase 1, dephosphorylating the bifunctional enzyme to raise F-2,6-BP and suppress PEPCK and G6Pase gene transcription (via FOXO1 phosphorylation).

Why can mammals not convert even-chain fatty acids into net glucose?

During mitochondrial β-oxidation, even-chain fatty acids are degraded exclusively into two-carbon acetyl-CoA units. The pyruvate dehydrogenase (PDH) complex reaction (pyruvate → acetyl-CoA + CO₂) is thermodynamically irreversible in vivo (Δ*G*°' = −33.4 kJ/mol), preventing direct conversion of acetyl-CoA to pyruvate. Furthermore, although acetyl-CoA enters the citric acid cycle by condensing with oxaloacetate, two carbons are lost as CO₂ at the isocitrate dehydrogenase and α-ketoglutarate dehydrogenase steps before oxaloacetate is regenerated, yielding zero net carbon gain. Plants, fungi, and bacteria bypass these decarboxylations via the glyoxylate cycle (using isocitrate lyase and malate synthase), which vertebrates lack.

How does acute ethanol consumption cause fasting hypoglycemia?

In hepatocytes, cytosolic alcohol dehydrogenase and mitochondrial acetaldehyde dehydrogenase oxidize ethanol sequentially to acetaldehyde and acetate while reducing two equivalents of NAD⁺ to NADH. In a fasting individual whose hepatic glycogen stores are depleted, the resulting surge in the cytosolic [NADH]/[NAD⁺] ratio drives the reversible equilibrium reactions of lactate dehydrogenase (pyruvate → lactate), malate dehydrogenase (oxaloacetate → malate), and glycerol-3-phosphate dehydrogenase away from gluconeogenic intermediates, starving gluconeogenesis of pyruvate and oxaloacetate.

What is Von Gierke disease (Glycogen Storage Disease Type Ia)?

Von Gierke disease (GSD Type Ia) is an autosomal recessive metabolic disorder caused by loss-of-function mutations in either the catalytic subunit of glucose-6-phosphatase (G6PC1) or the ER glucose-6-phosphate translocase (SLC37A4). Because hepatocytes and renal cells cannot hydrolyze G6P into free glucose during either glycogenolysis or gluconeogenesis, patients present with severe fasting hypoglycemia, lactic acidosis, hyperuricemia (gout), hyperlipidemia, and hepatomegaly from trapped G6P and glycogen accumulation.

1. Pilkis, S. J., & Granner, D. K. (1992). "Molecular Physiology of the Regulation of Hepatic Gluconeogenesis and Glycolysis." Annual Review of Physiology, 54(1), 885–909. https://doi.org/10.1146/annurev.ph.54.030192.004321
2. Hers, H. G., & Van Schaftingen, E. (1982). "Fructose 2,6-bisphosphate 2 Years After Its Discovery." Biochemical Journal, 206(1), 1–12. https://doi.org/10.1042/bj2060001
3. Jitrapakdee, S., St Maurice, M., Rayment, I., Cleland, W. W., Wallace, J. C., & Attwood, P. V. (2008). "Structure, Mechanism and Regulation of Pyruvate Carboxylase." Biochemical Journal, 413(3), 369–387. https://doi.org/10.1042/BJ20080709
4. Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017). "Regulation of Hepatic Glucose Metabolism in Health and Disease." Nature Reviews Endocrinology, 13(10), 572–587. https://doi.org/10.1038/nrendo.2017.80